Home LiteratureArticle Details
PMID: 9665981 Published · ppublish English Historical Article Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.

Clinical microbiology reviews ·Vol. 11 ·No. 3 ·1998-07-00 ·Pages 514-32

Glatman-Freedman A, Casadevall A

Abstract

Fifty years after the introduction of the first effective antimicrobial agents against Mycobacterium tuberculosis, this pathogen continues to be a tremendous public health problem. The rise in the number of resistant strains and the difficulties involved in the therapy of tuberculosis in immunocompromised AIDS patients have renewed the interest in the development of effective vaccines. To evaluate whether a potential vaccine against tuberculosis could prevent infection by eliciting a protective antibody response, we reviewed the history of antibody-mediated immunity against tuberculosis. Review of the literature of the past 100 years demonstrates that there is sufficient evidence to conclude that antibody-mediated immunity can modify the course of infection in certain situations. Based on our findings and on what is known in other systems, we propose that the role of antibody-mediated immunity to M. tuberculosis be reexamined, using advanced technology.

MeSH Terms
Animals History, 19th Century History, 20th Century Humans Immunization, Passive/history Mycobacterium tuberculosis/immunology Tuberculosis, Pulmonary/immunology,therapy
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Glatman-Freedman A
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York 10461, USA. afreedma@aecom.yu.edu
Casadevall A
References (74)
74 references, click to expand
  1. Intracellular neutralization of virus by immunoglobulin A antibodies.
    Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6901-5 PMID: 1323121
  2. Preliminary experiments on passive transfer of protective humoral antibodies in tuberculosis.
    Am Rev Tuberc. 1957 Aug;76(2):256-62 PMID: 13458706
  3. Prospects for new vaccines against tuberculosis.
    Trends Microbiol. 1995 Oct;3(10):401-4 PMID: 8564360
  4. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages.
    J Immunol. 1994 Apr 15;152(8):4070-9 PMID: 8144972
  5. The significance of antibodies to tuberculoprotein and polysaccharide in resistance to tuberculosis; interference with antibodies by these antigens.
    Am Rev Tuberc. 1956 Apr;73(4):547-62 PMID: 13302685
  6. Relationship between immunity and circulating antibodies, complement and tuberculopolysaccharide in tuberculosis.
    J Infect Dis. 1957 Sep-Oct;101(2):109-18 PMID: 13475868
  7. Immunological studies of the anticryptococcal factor of normal human serum.
    Mycopathologia. 1975 Jun 14;55(3):175-8 PMID: 807846
  8. Addition of immunotherapy with Mycobacterium w vaccine to multi-drug therapy benefits multibacillary leprosy patients.
    Vaccine. 1995 Aug;13(12):1102-10 PMID: 7491818
  9. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?
    Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):686-92 PMID: 1287946
  10. The relationship of acquired resistance, allergy, antibodies and tissue reactivities to the components of the tubercle bacillus.
    Am Rev Tuberc. 1946 Dec;54(6):564-73 PMID: 20286147
  11. Antibody response that protects against disseminated candidiasis.
    Infect Immun. 1995 Jul;63(7):2714-9 PMID: 7790089
  12. STREPTOMYCIN treatment of pulmonary tuberculosis.
    Br Med J. 1948 Oct 30;2(4582):769-82 PMID: 18890300
  13. A role for natural antibody in the pathogenesis of leprosy: antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes.
    Infect Immun. 1994 Jan;62(1):280-9 PMID: 8262640
  14. Tuberculin hemagglutination studies in active tuberculous infections, benign and virulent.
    Acta Paediatr. 1952 Jan;41(1):57-73 PMID: 14933014
  15. Studies on tubercle bacillus-monocyte relationship. I. Quantitative analysis of effect of serum of animals vaccinated with BCG upon bacterium-monocyte system.
    J Exp Med. 1956 Oct 1;104(4):455-65 PMID: 13367323
  16. Protective murine monoclonal antibodies to Cryptococcus neoformans.
    Infect Immun. 1992 Nov;60(11):4534-41 PMID: 1398966
  17. Antituberculous immunity: new solutions to an old problem.
    Rev Infect Dis. 1991 Sep-Oct;13(5):940-50 PMID: 1962110
  18. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
    Zentralbl Bakteriol. 1996 Aug;284(4):475-95 PMID: 8899968
  19. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
    Infect Immun. 1995 Feb;63(2):573-9 PMID: 7822024
  20. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival.
    J Exp Med. 1975 Jul 1;142(1):1-16 PMID: 807671
  21. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model.
    Vaccine. 1996 Jun;14(9):841-4 PMID: 8843625
  22. Specific serum agglutination of erythrocytes sensitized with extracts of tubercle bacilli.
    J Exp Med. 1948 Nov;88(5):521-8 PMID: 18892427
  23. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
    J Exp Med. 1997 Feb 17;185(4):685-94 PMID: 9034147
  24. Para-aminosalicylic acid in the treatment of tuberculosis.
    Lancet. 1946 Jan 5;1(6384):15 PMID: 21008766
  25. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody.
    J Immunol. 1995 Feb 15;154(4):1810-6 PMID: 7836766
  26. Studies on the effect of mycobacterial antibodies on skin-test reactivity to M. tuberculosis.
    Br J Exp Pathol. 1980 Apr;61(2):186-94 PMID: 6775663
  27. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum.
    J Clin Invest. 1990 Apr;85(4):1304-14 PMID: 2138634
  28. Antibody immunity and invasive fungal infections.
    Infect Immun. 1995 Nov;63(11):4211-8 PMID: 7591049
  29. Studies on tubercle bacillus-monocyte relationship. III. Conditions affecting the action of serum and cells; modification of bacilli in an immune system.
    J Exp Med. 1959 Jun 1;109(6):523-43 PMID: 13654626
  30. Increase of tuberculous infection in the organs of B cell-deficient mice.
    Clin Exp Immunol. 1996 Nov;106(2):312-6 PMID: 8918578
  31. Serum therapy revisited: animal models of infection and development of passive antibody therapy.
    Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702 PMID: 7985997
  32. Immunology of tuberculosis.
    Med Clin North Am. 1993 Nov;77(6):1235-51 PMID: 8231409
  33. Precipitin test for carbohydrate antibodies in human tuberculosis.
    Am Rev Tuberc. 1949 Jun;59(6):710-2 PMID: 18130356
  34. On the Use of Dog's Serum in the Treatment of Tuberculosis.
    Br Med J. 1891 Nov 14;2(1611):1041-3 PMID: 20753439
  35. TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.
    Br Med J. 1952 Oct 4;2(4787):735-46 PMID: 12978309
  36. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis.
    Scand J Immunol. 1997 Feb;45(2):115-31 PMID: 9042423
  37. Inhibition of the interaction of mycobacteria with Schwann cells by antimycobacterial antibodies.
    J Neuroimmunol. 1987 Mar;14(2):235-9 PMID: 3546373
  38. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.
    Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2483-8 PMID: 9122221
  39. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.
    J Clin Invest. 1988 Jun;81(6):1666-8 PMID: 2454947
  40. Mannosylated lipoarabinomannan interacts with phagocytes.
    Eur J Biochem. 1995 Jul 15;231(2):440-7 PMID: 7635156
  41. Correlations between plasma protein fractions, antibody titers, and the passive transfer of delayed and immediate cutaneous reactivity to tuberculin PPD and tuberculopolysaccharides.
    J Exp Med. 1955 Apr 1;101(4):391-420 PMID: 14354109
  42. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody.
    Infect Immun. 1987 Mar;55(3):749-52 PMID: 3546140
  43. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
    J Exp Med. 1995 Jan 1;181(1):405-9 PMID: 7807020
  44. PULMONARY TUBERCULOSIS TREATED BY SPAHLINGER'S SERUM.
    Br Med J. 1925 Jan 3;1(3340):43 PMID: 20771854
  45. Immunological and clinical features of smear-positive pulmonary tuberculosis in East Java.
    Tubercle. 1980 Dec;61(4):231-8 PMID: 6792756
  46. A CASE OF DISSEMINATED TUBERCULOSIS TREATED WITH MARMOREK'S SERUM.
    Br Med J. 1909 Nov 6;2(2549):1337-8 PMID: 20764733
  47. Humoral response to Mycobacterium tuberculosis in patients with human immunodeficiency virus infection.
    Tuber Lung Dis. 1992 Aug;73(4):187-91 PMID: 1477383
  48. NOTES ON CLINICAL TRIALS WITH MARMOREK'S ANTITUBERCULOUS SERUM.
    Br Med J. 1912 Feb 10;1(2667):299 PMID: 20766004
  49. Studies on tubercle bacillus-monocyte relationship. II. Induction of monocyte degeneration by bacteria and culture filtrate: specificity of serum and monocyte effects on resistance to degeneration.
    J Exp Med. 1957 Jan 1;105(1):25-37 PMID: 13385404
  50. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages.
    Infect Immun. 1991 May;59(5):1755-61 PMID: 1850379
  51. Hypothesis: how licensed vaccines confer protective immunity.
    Adv Exp Med Biol. 1996;397:169-82 PMID: 8718596
  52. Immunoglobulin G subclass responses to mycobacterial lipoarabinomannan in HIV-infected and non-infected patients with tuberculosis.
    Clin Exp Immunol. 1993 Jan;91(1):25-9 PMID: 8419082
  53. The immune spectrum in patients with pulmonary tuberculosis.
    Am Rev Respir Dis. 1981 May;123(5):556-9 PMID: 6786150
  54. Return to the past: the case for antibody-based therapies in infectious diseases.
    Clin Infect Dis. 1995 Jul;21(1):150-61 PMID: 7578724
  55. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
    Antimicrob Agents Chemother. 1994 Jul;38(7):1507-14 PMID: 7979280
  56. Resistance of high and low antibody responder lines of mice to the growth of avirulent (BCG) and virulent (H37Rv) strains of mycobacteria.
    Clin Exp Immunol. 1985 Jan;59(1):177-84 PMID: 3882283
  57. Some Statistics upon Sero-therapy in Tuberculosis.
    Trans Am Climatol Assoc. 1898;14:214-30 PMID: 21409180
  58. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.
    Infect Immun. 1990 Jun;58(6):1919-23 PMID: 2341184
  59. The spectrum of human tuberculosis.
    Clin Exp Immunol. 1977 Feb;27(2):230-7 PMID: 849655
  60. Antibody-mediated protection against intracellular pathogens.
    Trends Microbiol. 1998 Mar;6(3):102-7 PMID: 9582935
  61. Clinical interpretation of the Middlebrook-Dubos hemagglutination test.
    Am Rev Tuberc. 1950 Aug;62(2):121-7 PMID: 15432873
  62. The role of humoral factors in native and acquired resistance to tuberculosis.
    Am Rev Tuberc. 1957 Jul;76(1):90-102 PMID: 13444621
  63. Toxoplasma gondii: a monoclonal antibody that inhibits intracellular replication.
    Exp Parasitol. 1994 Nov;79(3):351-61 PMID: 7525337
  64. Blocking of Mycobacterium leprae adherence to dissociated Schwann cells by anti-mycobacterial antibodies.
    Scand J Immunol. 1989 Oct;30(4):505-9 PMID: 2683036
  65. The adsorption of proteins on erythrocytes treated with tannic acid and subsequent hemagglutination by antiprotein sera.
    J Exp Med. 1951 Feb;93(2):107-20 PMID: 14803635
  66. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.
    JAMA. 1995 Jan 18;273(3):220-6 PMID: 7807661
  67. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
    J Exp Med. 1996 Apr 1;183(4):1905-9 PMID: 8666947
  68. Multiplication of tubercle bacilli within mononuclear phagocytes in tissue cultures derived from normal animals and animals vaccinated with BCG.
    J Exp Med. 1953 Feb 1;97(2):235-45 PMID: 13022876
  69. Enhancement activity of anti-mycobacterial sera in experimental Mycobacterium bovis (BCG) infection in mice.
    Infect Immun. 1976 May;13(5):1301-6 PMID: 818022
  70. The significance of antigen-antibody reactions in tuberculosis.
    J Infect Dis. 1956 Jul-Aug;99(1):76-83 PMID: 13357776
  71. The interplay of an immune substance with tuberculopolysaccharide and its antibody in tuberculosis.
    J Infect Dis. 1958 Jul-Aug;103(1):52-60 PMID: 13575861
  72. STUDIES ON THE MECHANISM OF IMMUNITY IN TUBERCULOSIS : THE FATE OF TUBERCLE BACILLI INGESTED BY MONONUCLEAR PHAGOCYTES DERIVED FROM NORMAL AND IMMUNIZED ANIMALS.
    J Exp Med. 1942 Mar 1;75(3):247-68 PMID: 19871180
  73. Cryptococcus neoformans. I. Nonencapsulated mutants.
    J Bacteriol. 1967 Nov;94(5):1475-9 PMID: 6057803
  74. Failure of passive serum transfer of immunity against aerogenic tuberculosis in rabbits.
    Proc Soc Exp Biol Med. 1974 Jan;145(1):173-5 PMID: 4591392
Article Info
Journal
Clinical microbiology reviews
Abbr.
Clin Microbiol Rev
ISSN
0893-8512
DOI
10.1128/CMR.11.3.514
Email
afreedma@aecom.yu.edu
Published
1998-07-00
Pages
514-32
Language
English
Region
United States
NLM ID
8807282
PMCID
PMC88894
Subset
IM
Grants
NIAID NIH HHS · R01 AI033142 · United States
NIAID NIH HHS · R01 AI033774 · United States
NIAID NIH HHS · 1 T32 AI07501-01 · United States
NIAID NIH HHS · AI-33774 · United States
NIAID NIH HHS · T32 AI007501 · United States
NIAID NIH HHS · R37 AI033142 · United States
NIAID NIH HHS · AI-33142 · United States
External Links
PubMed source DOI: 10.1128/CMR.11.3.514 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2